Bausch Health (BHC) releases Phase 3 RED-C hepatic encephalopathy trial results

Rhea-AI Filing Summary

Bausch Health Companies Inc. filed a current report to share that it has issued a press release about the results of its global Phase 3 RED-C clinical program. This study evaluated amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy.

The company furnished the press release as Exhibit 99.1 and stated that this information is being provided under Regulation FD, meaning it is intended as a broad, fair disclosure to the market. The furnished material is not considered "filed" for liability purposes under the Exchange Act or automatically incorporated into other securities filings unless specifically referenced.

Insights

Biopharma & SEC disclosure analyst

Bausch Health furnishes Phase 3 RED-C trial results via Regulation FD.

Bausch Health has disclosed that it released results from the global Phase 3 RED-C program in adults with liver cirrhosis, testing an amorphous-rifaximin solid soluble dispersion to prevent hepatic encephalopathy. The details and outcome of the trial are contained in a press release that is furnished as Exhibit 99.1.

The use of Item 7.01 indicates this is Regulation FD information, emphasizing broad market access to the same data at the same time. Because the excerpt does not specify whether the results are favorable or unfavorable, the commercial and financial implications remain unclear based on this text alone.

Investors looking to understand the potential impact on Bausch Health’s liver disease portfolio would need to review the January 23, 2026 press release referenced as Exhibit 99.1, which should contain the efficacy and safety data from the RED-C program.

0000885590false00008855902026-01-132026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

January 23, 2026

Date of report (Date of earliest event reported)

 Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

British Columbia

,

Canada

001-14956

98-0448205

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Shares, No Par Value			BHC			New York Stock Exchange			Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐            

Item 7.01 Regulation FD Disclosure

On January 23, 2026, Bausch Health Companies Inc. issued a press release announcing the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

This information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished as part of this Current Report on Form 8-K:

Number						Description
99.1						Press Release dated as of January 23, 2026
101.SCH						XBRL Taxonomy Extension Schema Document
101.LAB						XBRL Taxonomy Extension Label Linkbase Document
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

____________________________________

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 23, 2026

			BAUSCH HEALTH COMPANIES INC.
By:			/s/ Jean-Jacques Charhon
			Jean-Jacques Charhon
			Executive Vice President, Chief Financial Officer
			(Principal Financial Officer)

FAQ

What did Bausch Health (BHC) disclose in this 8-K?

Bausch Health reported that it issued a press release announcing results from the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion in adults with liver cirrhosis for primary prevention of hepatic encephalopathy.

What is the Phase 3 RED-C clinical program mentioned by Bausch Health (BHC)?

The Phase 3 RED-C clinical program is a global study in adults with liver cirrhosis evaluating amorphous-rifaximin solid soluble dispersion for the primary prevention of hepatic encephalopathy.

Where can investors find the detailed Phase 3 RED-C results for Bausch Health (BHC)?

The detailed results are contained in Bausch Health’s press release dated January 23, 2026, which is furnished as Exhibit 99.1 to this 8-K and incorporated by reference into the report.

Is the Bausch Health (BHC) Phase 3 RED-C information considered "filed" with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for purposes of Section 18 of the Exchange Act and is not incorporated into other filings unless specifically referenced.

Which exhibit in the Bausch Health (BHC) 8-K contains the press release on RED-C results?

Exhibit 99.1 to the 8-K is the press release dated January 23, 2026, that announces the results of the Phase 3 RED-C clinical program.

Who signed the Bausch Health (BHC) 8-K related to the RED-C trial results?

The 8-K was signed on behalf of Bausch Health Companies Inc. by Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, identified as the Principal Financial Officer.